occur before cleavage but after sulfinic or sulfonic acid modification, as we were able to observe these derivatives in our peptide analysis of proMMP-9. To confirm the pathophysiological relevance of these findings, we performed the same ischemia and reperfusion experiments after nNOS inhibition with 3br7NI, which is known to be neuroprotective and decrease stroke size. Under these conditions with NO formation blocked, the sulfinic and sulfonic acid oxidation products of activated MMP-9 were not observed in our MALDI-TOF analysis (Fig. 4C ). One caveat with these findings is that nNOS deletion or NOS inhibition diminishes stroke damage, and hence one could argue that other stroke-related processes responsible for MMP activation would be reduced. Nonetheless, taken together with the data demonstrating S-nitrosylation of MMPs and our finding that MMPs activated in this manner cause neuronal apoptosis in vitro, it is likely that NO activation of MMPs participates in neuronal injury in vivo.
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S-Nitrosylation and subsequent oxidation of protein thiol in the prodomain of MMP-9 can thus lead to enzyme activation, and homologous MMPs may be activated in a similar manner. This series of reactions confers responsiveness of the extracellular matrix to nitrosative and oxidative stress. Such insults are relevant to a number of pathophysiological conditions, including cerebral ischemia and neurodegenerative diseases. Extracellular proteolytic cascades triggered by MMPs can disrupt the extracellular matrix, contribute to cell detachment, and lead to a form of apoptotic cell death known as anoikis, similar to that observed in our neuronal cultures (27) . The elucidation of an extracellular signaling pathway to neuronal apoptosis involving NO-activated MMPs may contribute to the development of new therapies for stroke and other disorders associated with nitrosative and oxidative stress. Axons of the adult mammalian CNS possess an extremely limited ability to regenerate after injury, largely because of environmental factors preventing axon growth (1, 2) . Characterization of the molecular mechanisms limiting axonal regeneration holds promise for the development of therapeutics to promote recovery after human CNS injury (3, 4) . Two factors limiting CNS regeneration, Nogo and MAG, are produced by oligodendrocytes and are distributed in the myelin that ensheathes CNS axons (5, 6) . Successful axon regeneration in the peripheral nervous system can be attributed to the absence of Nogo in myelinating Schwann cells, the rapid clearance of MAG by macrophages, and the induction of regeneration-associated genes (1-6). The recently identified Nogo receptor (NgR) is a leucine-rich repeat (LRR) protein that is GPI-anchored to the outer leaflet of the plasma membrane and binds a discrete cellsurface Nogo domain, Nogo-66 (7). MAG is recognized as a sialic acid-binding SIGLEC (sialic acid-dependent immunoglobulin-like family member lectin) protein with an affinity for gangliosides GD1a and GT1b (8) (9) (10) (11) (12) (13) (14) . It has been suggested that these gangliosides might serve as axonal MAG receptors (11) . No axonal proteins with high affinity for MAG have been identified. Here, we find that NgR serves as a receptor for MAG as well as Nogo-66, indicating that blockade of this one receptor may reverse the action of two inhibitors of CNS axonal regeneration. NgR lacks an intracellular component, suggesting that it serves as the primary Nogo-66 binding site while an associated transmembrane coreceptor subunit mediates intracellular signal transduction (7) . We sought to identify a coreceptor component by using an expression-cloning strategy based on the binding of a soluble fusion protein composed Department of Neurology and Section of Neurobiology, Yale University School of Medicine, New Haven, CT 06510, USA.
*To whom correspondence should be addressed. Email: stephen.strittmatter@yale.edu of alkaline phosphatase (AP) and the entire NgR ectodomain. In initial studies, the soluble AP-NgR fusion protein bound to neurons in a saturable manner and with high affinity (15) , indicating a potential coreceptor binding site for NgR. The AP-NgR fusion protein was used to screen pools of an adult mouse brain cDNA expression library transfected into COS-7 cells. This screen demonstrated that the NgR can self-associate, with 6 out of 10 positive pools containing a cDNA encoding NgR itself (see supporting online material) and mediating binding of AP-Nogo-66 as effectively as AP-NgR. NgR self-association is clear in assays of AP-NgR binding to NgR-expressing cells (Fig. 1A) . The 4 remaining positive pools from the screen do not exhibit AP-Nogo-66 binding. A single cDNA species, Clone 91, was isolated by sib selection from one of these positive pools. Transfection of Clone 91 cDNA into COS-7 cells resulted in the expression of a binding site with high affinity for AP-NgR; the binding affinity (K D ) for this is 15 nM (Fig. 1B) . Neither AP (15) nor AP-Nogo-66 (Fig. 1A) binds to Clone 91-expressing cells.
To our surprise, DNA sequence analysis indicated that Clone 91 does not encode a neuronal Nogo coreceptor but rather a myelin-derived inhibitor of axon regeneration, MAG. Sib selection from all of the three other non-NgR-positive pools also yielded MAG. This suggests that NgR is a ligandbinding receptor for both Nogo-66 and MAG. Indeed, using soluble AP-MAG-ectodomain, MAG binding to cell-surface NgR exhibits a K D of about 20 nM (Fig. 1C) . This binding affinity is consistent with the potency of soluble MAG as an axonal growth cone-collapsing agent (16) . Because MAG is known to bind sialic acid, we considered whether the binding event might be dependent on sialic acid residues on NgR. Neuroaminidase treatment strips sialic acid from COS-7-expressing exogenous NgR and neurons that express endogenous NgR but does not alter AP-MAG binding (Fig. 1, D and E) . Thus, neither sialic acid on NgR nor sialic acid on cell-surface gangliosides appears essential for AP-MAG binding to NgR-expressing cells. Alternatively, phosphatidyl-inositol-specific phospholipase C (PI-PLC) treatment to remove NgR and other GPI-anchored proteins (but not gangliosides) from the cell surface completely abolishes AP-MAG binding to NgR-expressing COS-7 cells and neurons (Fig. 1, D and E). These data are consistent with NgR being the primary high-affinity binding site for MAG on neurons. The partial sialidase sensitivity of neuronal MAG binding sites observed in some previous reports (8) (9) (10) 13) may reflect the fact that solid-phase assays favor multivalent, low-affinity interactions of MAG with sialic acid residues.
One explanation for AP-MAG binding to (Fig. 1F) . The MAG-NgR interaction is not modulated by the presence of 2 g/ml of ganglioside GT1b; bound NgR in the presence of GT1b is 91 Ϯ 9% (mean Ϯ SEM) of that without GT1b. Fc-MAG was also immobilized in anti-human IgG-coated microtiter wells and exposed to AP-NgR or AP-Nogo-66. Selective binding of NgR to MAG is detectable as bound AP activity (Fig. 1G ).
If NgR is indeed a functional receptor for MAG in neurons, removal of NgR from the axonal surface should prevent MAGinduced inhibition of outgrowth. PI-PLC pretreatment of embryonic day 14 (E14) chick DRG neurons removes GPI-anchored proteins, including NgR, from the neuronal cell surface (7 ). This pretreatment does not alter basal growth cone morphology but renders neurons insensitive to Fc-MAGinduced growth cone collapse (Fig. 2, A  and B) . To selectively interfere with NgR action, we tested a dominant-negative interfering form of NgR. The truncated soluble NgR fragment containing amino acids 27 to 310 (NgR-Ecto) selectively antagonizes Nogo-66 and myelin inhibition of neurite outgrowth (17 ) . The presence of NgR-Ecto protein also reverses MAG inhi- bition of neurite outgrowth (Fig. 2, C and  D) . The specificity of NgR-Ecto blockade is apparent in its lack of effect on outgrowth inhibition by a reagent that does not bind to NgR, Amino-Nogo (Fig. 2D) (17 ) . Together, these data indicate that NgR is essential for MAG inhibition of axon outgrowth.
The sensitivity of neurons to MAG is regulated developmentally in rodents (18), with MAG-dependent inhibition beginning only in the early postnatal period. If NgR mediates MAG action, then NgR expression may follow a similar pattern. Indeed, NgR immunohistology reveals strong expression in adult (P64) mouse DRG neurons, but no detectable expression in E17 mouse DRG (Fig. 3A) . We confirm that NgR-expressing adult DRG neurons are inhibited by MAG and that this inhibition is abolished in the presence of NgR-Ecto or by treatment with PI-PLC (Fig. 3B) . By contrast, embryonic DRGs lack NgR and are not sensitive to MAG in the neurite outgrowth assay (Fig. 3,  B) . For these neurons, MAG sensitivity is correlated with NgR expression. This correlation is likely to be widespread, because a variety of postnatal neurons are responsive to MAG (19) , and all adult CNS neurons appear to express NgR (20) .
To investigate whether NgR expression is sufficient to convert MAG-insensitive neurons to a state in which MAG is inhibitory, we expressed NgR in early embryonic DRG neurons that are not inhibited by MAG. A recombinant herpes simplex virus (HSV) preparation drives expression of NgR in chick E7 DRG neurons and supports both Nogo-66 and MAG action, as determined in growth cone-collapse assays (Fig. 3, C and  D) . Thus, NgR can mediate both Nogo-66 and MAG signaling.
To understand the mechanism by which NgR is stimulated by either Nogo or MAG, we sought to characterize the domains on the NgR responsible for receptor-MAG interaction by deletion analysis. Binding of Nogo-66 is known to require all eight LRRs, but not the 140 -amino acid domain connecting the LRRs to the GPI anchorage site (17) . MAG binds to the same region of NgR as does Nogo-66, requiring all of the LRR domains but not the 140 -amino acid domain (Fig. 4A) . Deletion of any two sequential LRRs in NgR abolishes AP-MAG binding (15) . This raises the possibility that Nogo-66 and MAG might compete for the same binding site in the NgR LRRs. However, excess Nogo-66 does not prevent MAG-NgR binding (15) . Thus, the two myelin-derived outgrowth inhibitors appear to possess separate binding sites within the same domain of NgR. To verify the distinctness of these sites in axons, the selective Nogo-66 antagonist peptide NEP1-40 was included in neurite outgrowth assays on MAG or Nogo-66 substrate. We have shown that peptide NEP1-40, derived from the amino-terminal fragment of the Nogo-66 domain, antagonizes Nogo-66 activity (21) . Here, we show that, although NEP1-40 blocks Nogo-66 action, it does not reduce MAG inhibition of neurite outgrowth (Fig. 4B) .
This study identifies NgR as a receptor (20) . Thus, NgR must be considered a general receptor for restrictive effects of CNS myelin on axon growth in the adult mammalian CNS (Fig. 4C) . Although MAG and Nogo-66 both bind to the LRRs of NgR, they appear to bind independently. This provides an explanation for similar but additive effects of Nogo and MAG on inhibition of axon growth. Evidence indicates that the NgR ligands, Nogo and MAG, are the two primary inhibitors in CNS myelin. Myelin prepared from mice lacking Nogo-A exhibits reduced inhibition of axon outgrowth, and the residual inhibitory activity is abolished by antibodies to MAG (22) . Because one receptor mediates the action of both known myelin-derived inhibitors, interference with NgR function after CNS axonal injury may significantly alleviate myelin-dependent limitation of axonal regeneration.
